Bionano Corporate Overview

December 2024





Safe harbor statement - This presentation contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. Words such as "may," "will," "expect," "plan," anticipate," "estimate," "intend," "should," "believe," "would," "could," "potential," "outlook," "guidance," "goal" and similar expressions (as well as other words or expressions referencing future events, conditions or circumstances and the negatives thereof) convey uncertainty of future events or outcomes and are intended to identify these forward-looking statements. Forward-looking statements include statements regarding our intentions, beliefs, projections, outlook, analyses or current expectations concerning, among other things: (i) our expectations regarding product uptake, revenue growth, market development and adoption of OGM, including growth in publications highlighting the utilization of OGM; (ii) our growth prospects and future financial and operating results; (iii) growth of our OGM system installed base and sales of our flowcells; (iv) increase in the adoption and utilization of OGM; (v) the impact of our investment in R&D and commercial and educational initiatives, including timely and successful launch of our planned product developments and clinical study results; (vi) our ability to stay in front of competitors' improvements; (vii) our estimates of anticipated market opportunity and underlying assumptions; (viii) our guarterly and annual revenue outlook; (ix) the anticipated benefits and success of our collaborations; (x) the anticipated benefits of our cost savings initiatives and our ability to realize the planned savings; and (xi) other statements that are not historical facts.

Each of these forward-looking statements involves risks and uncertainties. Actual results or developments may differ materially from those projected or implied in these forward-looking statements. Factors that may cause such a difference include the risks and uncertainties associated with: (i) the impact of global and macroeconomic events, such as recent and potential future bank failures, inflation, supply chain disruptions, and the ongoing Ukraine-Russia and Israel-Hamas conflicts and related sanctions, on our business and the global economy; (ii) challenges inherent in developing, manufacturing and commercializing products; (iii) our ability to further deploy new products and applications and expand the markets for our technology platforms; (iv) third parties' abilities to manufacture our instruments and consumables; (v) our expectations and beliefs regarding future growth of the business and the markets in which we operate; (vi) the accuracy of our estimates; (vii) our ability to obtain financing to fund our operations and continue as a "going concern"; (ix) the success of our cost savings initiatives and our ability to realize the planned savings; (x) he success of products competitive with our own; (xi) changes in our strategic and commercial plans; and (xii) the application of generally accepted accounting principles which are highly complex and involve many subjective assumptions. We are under no duty to update any of these forward-looking statements as representing our views as of any date subsequent to the date of this presentation. Except as required by law, neither we nor any other person assumes responsibility for the accuracy and completeness of the forward-looking statements contained in this presentation.

More information about these and other statements, risks and uncertainties is contained in our filings with the U.S. Securities and Exchange Commission, including, without limitation, our Annual Report on Form 10-K for the year ended December 31, 2023 and in other filings subsequently made by us with the Securities and Exchange Commission. All forward-looking statements contained in this presentation speak only as of the date on which they were made and are based on management's assumptions and estimates as of such date. We do not undertake any obligation to publicly update any forward-looking statements, whether as a result of the receipt of new information, the occurrence of future events or otherwise except as required by law.

To supplement our financial results reported in accordance with U.S. generally accepted accounting principles (GAAP), we have provided certain non-GAAP financial measures, including gross margin and operating expense in this presentation. A description of these non-GAAP financial measures as well as a reconciliation to the nearest GAAP financial measures are included at the end of the Company's earnings release issued associated with this presentation, which has been posted on the investor relations page of the Company's website. Because of the non-standardized definitions of non-GAAP financial measures, the non-GAAP financial measures as used in this presentation and the associated reconciliation table have limits in its usefulness to investors and may be calculated differently from, and therefore may not be directly comparable to, similarly titled measures used by other companies. For certain non-GAAP financial measures we do not provide guidance for the most directly comparable GAAP measures without unreasonable effort due to the unavailability of reliable estimates for certain components which are not within our control and may vary greatly between periods and could significantly impact our financial results calculated in accordance with GAAP.

We believe that non-GAAP financial measures in this presentation are useful to investors and analysts as a supplement to our financial information prepared in accordance with GAAP for analyzing operating performance and identifying operating trends in its business. We believe these measures allow for greater transparency with respect to key financial metrics we use in assessing our own operating performance and making operating decisions. These non-GAAP financial measures are not meant to be considered in isolation or as a substitute for comparable GAAP measures and should be read in conjunction with our consolidated financial statements prepared in accordance with GAAP.

Bionano is transforming the way the world sees the genome

Pioneered a method for structural variant (SV) detection called optical genome mapping (OGM)

- OGM consolidates 3 legacy cytogenetic methods into one assay
- · It complements sequencing as a new tool
- **Consistently finds more actionable variants** in days vs. weeks at a substantially lower cost

Commercial stage, tools & Dx Co with TTM of \$36.6 M in sales with platform for genome analysis

- Strategic focus on driving growth in utilization of OGM consumables supported by the existing install base of ~360 OGM systems
 - Revenue growth through *menu expansion* and end-to-end workflow improvements
- Targeting academic medical centers and commercial reference labs: research applications are cancer, cell and gene therapy, and constitutional genetic disease
- Estimated OGM TAM: \$10B and 10K labs running ~10M samples/year + 2.4M samples for cell and gene therapy

Executive Team



Erik Holmlin, PhD President and Chief Executive Officer *Joined 2011*




Mark Oldakowski Chief Operating Officer *Joined 2014*




Alka Chaubey, PhD Chief Medical Officer Joined 2020

Traditional methods in use today for SV detection are outdated and leave a significant number of questions unanswered

Traditional cytogenetics requires multiple methods that are labor intense, time-consuming, repetitive & costly



Clinical utility of traditional cytogenetic analysis is severely limited




As many as **20%** of prognostic scores for Rx selection may be wrong

86% of cell & gene therapy programs are halted, due partly to limitations in genome analysis tools




Source: L.E.K interviews, research and analysis; Statistical Bulletin on Health Development in China 2021; Department of Woman and Child Health Services of the NHC; management estimates; Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027 (marketresearch.com); Cell & Gene Therapy Market - Global Outlook & Forecast 2022-2027 (researchandmarkets.com)

OGM detects all classes of SVs in one assay, replacing classical cytogenetics, and bridges the gap to sequencing



OGM uses single molecule imaging of sequence specific patterns on ultra-high molecular weight DNA to reveal SVs




Published studies consistently show that OGM outperforms long-read sequencing for detection of structural variations

Human ref genomes											
Chaisson et al. 2019	Inversion >5 kbp				66					33	
Zook et al., 2020	Ins/del >1kbp			50					50		
Ebert et al., 2022	Ins/del >5kbp				72					28	
Purobsky et al., 2022	Inversions >8kbp			57					43		
Cancer genomes											
Talsania et al., 2022	Breast (NP)		23					77			
Talsania et al., 2022	Breast		25					75			
	0	% 10	% 20	0% 30	9% 40	9% 50	0% 60)% 70	0% 80	90%	0% 100%
			∎Fr	action det	ected by s	sequencin	ig ∎Fract	tion misse	ed by sequ	lencing	

Chaisson, et al. Nat Commun. 2019;10(1):1784., Zook, et al. Nat Biotechnol. 2020;38(11):1347-1355; Ebert, et al. Science. 2021;372(6537). Porubsky, et al. Cell. 2022;185(11):1986-2005.e26. Talsania, et al. Genome Biol. 2022;23(1):255.

Bionano provides an end-to-end solution for comprehensive structural variant detection with OGM




End -to- End Solution

- Sample-to-interpreted report in as few as 3 days for up to 10,000 samples per year per instrument
- VIA[™] software integrates OGM data for all classes of SVs together with NGS and array data in a single view
- Computation solutions developed in collaboration with NVIDIA
- Bionano sells and supports all components of the workflow


Strategy Update: Our Plan to Succeed



Strategic pillars underpinning the transformed Bionano




Key publications show evidence of OGM as a superior alternative to traditional cytogenetic methods & sequencing (NGS or LRS) for SV detection




OGM revealed additional pathogenic variants in 13% of study subjects

https://www.nature.com/articles/s41375-022-01652-8#Abs1



https://www.nature.com/articles/s41525-021-00241-5



https://www.embopress.org/doi/epdf/10.15252/embj.2023114188

Strategic assemblance of end-to-end OGM workflow



Q1' 2017 Commercial launch of Saphyr ® system

bionano



Q4' 2021

Acquires BioDiscovery software solution NxClinical[™] for genome-wide variant analysis from NGS and microarray data types

Q1' 2024

Full commercial launch of Stratys™ system, which offers high throughput capabilities for new clinical and translational research applications



Q1' 2018

Introduces DLS chemistry, method for improving its singlemolecule optical genome maps



er Lin Mar

Q4' 2022

Acquires Purigen Biosystems automated nucleic acid extraction and purification solutions using proprietary isotachophoresis (ITP) technology on the Ionic® system; OGM kit anticipated second half 2024

Q2' 2023


Launch of VIA[™] software, a new platform for visualization, interpretation and reporting across OGM, microarray and NGS data types. Version with expanded capabilities released in May 2024



Financial Review



Financial highlights as of September 30th, 2024



• Q3 revenues: \$6.1M (-35% vs Q3'23)

- \$6.6M core product & software sales offset by a \$0.5M write-down of aged receivables
- GAAP gross margin of (139)%; non-GAAP gross margin 26%
- GAAP OpEx \$35.5M; non-GAAP OpEx \$16.1M
- Q3 OGM installed base: 368 (+22% vs Q3'23)
- Q3 flowcells sold: 7,835 (+27% vs Q3'23)

\$23.4M* Cash, Cash Equivalents, and Available-for-Sale Securities at End Q3 2024

Important steps to help us deliver against our vision



Equity Financings

- ✓ Registered direct offering in April 2024, with gross proceeds of ~\$10M
- ✓ Registered direct offering in July 2024, with gross proceeds of ~\$10M
- ✓ Registered direct offering in October 2024, with gross proceeds of ~\$3M
- ✓ Since end of 3Q ATM \$1.2M



Projected Cost Savings

✓ \$100M projected cumulative annual operating expense reduction by Q1 2025, compared to Q1 2023

A highly disciplined approach will position company for future streamlined growth

Significant milestone for OGM with establishment of Category I CPT code for OGM in hematological malignancy analysis

- Editorial panel of the American Medical Association (AMA) established a new Category I Current Procedural Terminology (CPT) code for the use of OGM in cytogenomic genome-wide analysis to detect structural and copy number variations related to hematological malignancies
- CPT code is a key component in obtaining reimbursement for the Bionano Laboratories
 OGM-Dx[™] HemeOne laboratory developed test from third party payors



American Medical Association (AMA) CPT Code for OGM

Code #	88XX0
Final Code #	TBD
Code Type	NEW
Category	Molecular Pathology; Optical Genome Mapping
Long Code Descriptor	Cytogenomic genome-wide analysis, hematologic malignancy, structural variations and copy number variations, optical genome mapping (OGM)

Bionano is focused on accelerating revenue growth, operating efficiently, and raising capital that will allow us to extend our cash runway

Streamlined Business Focus

- OGM utilization across clinical sitesLeverage existing customer / install
 - base to increase utilization and drive menu expansion

Adoption of VIA[™] software driving

- Maintain initiatives for OGM reimbursement
- Improve GM profile: COGS & sample pull through

2024 Guidance



OGM FY'24 Total Revenue Guidance: **\$28 - \$30M**



OGM Installed Base YE'24: **370 – 380 systems**




4Q'24 Revenue Guidance: **\$6.0 - \$7.0M**

Thank you.







Traditional Cytogenetic Lab Workflow



Vs. The OGM Workflow



OGM Has a Unique Position in the Genomics Market



Clinical Trial Sites and PIs Influence Guidelines and Reimbursement



Diagnostic Laboratory

Cytogenetics

Experimental Pathology

World renowned geneticist

bionano

National Comprehensive Cancer Network

Recent Publications from Our Clinical Trials Span our Target Markets

REFERENCE	COHORT SIZE	G	enetic Dise	ease	Cancer					
		FSHD	Prenatal	Postnatal	AML/CML//MP N/MDS	ALL/CLL	Lymphoma	MM/PCM	Solid Tumo	
University of Iowa Stence, et al., 2021	351	•								
University of Augusta Sahajpal, et al., 2023	114		•							
Ningbo Women & Children Xie, et al., 2024	204		•							
Multisite trial Iqbal, et al., 2023	404									
Multisite trial Broeckel, et al., 2024	597			•						
Radboud University Neveling et al., 2021	52				●	•		•		
Multi-site Pang et al. 2022	80				●	•		•		
Augusta, Emory Sahajpal et al. 2022	69				●			•		
M.D. Anderson Yang et al., 2022	101				●					
Cancer Genomics Consortium Levy et al., 2022	100									
Hannover Medical School Lühmann et al., 2023	142					•				
Penn State Med Goldrich et al., 2021	20								•	

